Overview
Lobbying Costs
700,000€ - 799,999€
Financial year: Jan 2022 - Dec 2022
Lobbyists (Full time equivalent)
2.2 Fte (4)
Lobbyists with EP accreditation
2
High-level Commission meetings
10
Lobbying Costs over the years
-
Info
Gilead Sciences (GILD)
EU Transparency Register
258845020786-10 First registered on 23 Feb 2016
Goals / Remit
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 38 countries worldwide.
Main EU files targeted
EU initiatives relevant to HIV/AIDS, Hepatitis B & C and oncology
- ATMP Regulation
- EU IP policy
- EU research policy
- EU trade policy
- Health Systems Performance Assessment
- Health Technology Assessment & Market Access
- Industrial policy
- Outcomes-based healthcare systems
- Orphan Medicinal Products Regulation
- Paediatric Regulation
- Digital Health
- Europe's Beating Cancer Plan
- Blood, tissues and cells legislation
- Sustainable Development Goals
- EC Pharma Strategy
- European Health Union
- EU4Health
- Re-opening of the general pharmaceutical legislationAddress
Head Office
333 Lakeside Foster City
California CA94404
UNITED STATESEU Office
Park Lane Culliganlaan 2
Diegem 1831
BELGIUMWebsite
-
People
Total lobbyists declared
4
Employment time Lobbyists 100% 2 10% 2 Lobbyists (Full time equivalent)
2.2
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
2 accreditations were / are live (in bold) for the selected state of 04 Dec 2023
Name Start date End Date Mr Andrea Zanaglio 12 Oct 2023 11 Oct 2024 Mr William SCHARF 10 Oct 2023 09 Oct 2024 Mr William SCHARF 12 Oct 2022 10 Oct 2023 Mr Andrea Zanaglio 12 Oct 2022 12 Oct 2023 Ms Claire Albano 31 Aug 2019 01 Sep 2020 Mr Davis MARK 16 Oct 2018 01 Nov 2019 Ms Claire Albano 12 Jun 2018 12 Jun 2019 Mr Davis MARK 20 Jul 2017 07 Jul 2018 Mr Julien Patris 20 Jul 2017 01 Dec 2017 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
EFPIA: http://www.efpia.eu
Europabio http://www.europabio.org
EUCOPE http://www.eucope.org
AMCHAM EU: http://www.amchameu.eu
BRITCHAM EU: https://www.britcham.eu/Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2022 - Dec 2022
Lobbying costs for closed financial year
700,000€ - 799,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount fipra international srl 200,000€ - 299,999€ Intermediaries for current year
Name fipra international srl Closed year Costs
700,000€ - 799,999€
Other financial info
This estimate includes costs attributable to covered activities, including consulting fees, meeting costs and the pro-rata salary and travel costs of Gilead Sciences' staff involved in representation to the European institutions, based on the proportion of employee time spent on these activities. The two dedicated 100% FTEs started in September 2022 and are calculated pro-rata for the financial year of 2022.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Support to and participation in multi-stakeholder initiatives advocating for policy initiatives towards elimination of hepatitis C, promoting improved long term health outcomes for people living with HIV and exploring policy options to improve access to cancer treatments and ATMPs across Europe;
Sponsorship of a journalistic investigation on HIV independently carried out by POLITICO Europe.Other activities
None declared
Meetings
Meetings
10 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.
-
Date 22 Mar 2023 Location Brussels Subject Discussed Gilead’s manufacturing operations in Ireland and globally. Gilead outlined their concerns with the soon to be published EU Pharmaceutical strategy, with particular emphasis on unmet medical needs, regulatory data protection and innovation Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Patricia Reilly (Cabinet member)
-
Date 11 Jun 2021 Location Brussels, virtual meeting Subject Exchange of views on joint procurement and scientific assessment of Remdesivir Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 07 Dec 2020 Location virtual meeting Subject Exchange of views, update on Remdesivir Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 16 Oct 2020 Location Brussels - virtual meeting Subject Exchange of views - update on Remdesivir Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 09 Sep 2020 Location Phone call Subject Discussions/update on Remdesivir Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 06 Jul 2020 Location Brussels Subject VC meeting: Exchange of views on the forthcoming Pharmaceutical Strategy Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 06 May 2020 Location Brussels Subject VC meeting on remdesivir as a developmental medicine, the clinical trial programme, actions taken in respect of making remdesivir available via a compassionate use, Member States' needs and distribution should it receive market authorisation Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 07 Apr 2020 Location Brussels Subject Discussion on medicines (potential treatments, production, clinical trials, access to results) Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
-
Date 25 Sep 2017 Location Brussels Subject Hepatitis B and C, HIV Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Arunas Vinciunas (Cabinet member)
-
Date 19 Jun 2017 Location Brussels Subject economic situation within the EU, investment climate, deepening of the EMU, social dimension of the European project, financial regulations and markets Cabinet Cabinet of Vice-President Valdis Dombrovskis Portfolio Euro and Social Dialogue, also in charge of Financial Stability, Financial Services and Capital Markets Union Attending - Elina Melngaile (Cabinet member)
- Valdis Dombrovskis (Vice-President)
Other Lobbyists